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BACKGROUND: Atrial fibrillation (AF) patients with diabetes (DM) are at increased risk of 
cardiovascular events and have higher related morbidity and mortality. 
PURPOSE: To compare clinical characteristics, cardiovascular adverse outcomes and quality of 
anticoagulation in AF patients with and without DM.  
METHODS: AF patients from the Spanish national, multicentric, prospective FANTASIIA 
registry were included. Patients received oral anticoagulation (vitamin K antagonists (VKA) or 
direct oral anticoagulants (DOAC)) for at least 6 months before inclusion. Baseline clinical 
characteristics and comorbidities were recorded. After 2-years follow-up, the association 
between adverse events and the presence of DM was evaluated.  
RESULTS: 1956 individuals (mean age 73.8±9.5 years, 56% male) were analysed; of these, 
574 (29.3%) had DM. Diabetic patients had increased prevalence of other risk factors such as 
hypertension (90.6% vs 76.1%; p<0.001), renal disease (21.4% vs 15.9%; p<0.001) and heart 
failure (39.1% vs 24.7%; p<0.001). A rhythm control strategy was applied less often in diabetic 
patients vs non-diabetics (33.6% vs 40.1%; p=0.007).  
After a median follow-up of 1077 days (IQR 766-1113 days), diabetic patients had higher risk of 
total mortality (16.9%/year vs 11.4%/year; p<0.001), cardiovascular mortality (9.1%/year vs 
3.9%/year; p<0.001) and MACE (12.9%/year vs 6.8%/year; p<0.001). Patients with DM had 
increased total mortality risk [HR 1.58 (95IC% 1.20-2.07); p<0,001], cardiovascular mortality 
[HR 2.40 (95IC% 1.17-3.53); p<0.001] and MACE [HR 2.03 (IC95% 1.47-2.80); p<0.001]. DM 
patients had poorer anticoagulation control (time in therapeutic range: 58.52±24.37% vs 
62.68±25.31%; p=0.002). Among diabetic individuals, those with lower TTR showed higher risk 
of cardiovascular death [(14.12 vs 4.89%;p=0.001 for TTR<65 vs ≥65%);(13.36 vs 
4.55%;p=0.003 for TTR<70 vs ≥70%)] and MACE [(16.79 vs 9.78%;p=0.03 for TTR<65 vs 
≥65%);(16.44 vs 9.09%;p=0.03 for TTR<70 vs ≥70%)]. Multivariate analysis showed an 
independent association between the presence of DM and cardiovascular mortality [HR 1.73 
(IC95% 1.07-2.80); p=0.024].  
CONCLUSION: Diabetic patients with AF have more associated comorbidities. Quality of 
anticoagulation control with vitamin K antagonists in these subjects was poorer than in non-
diabetic patients. Lower TTR was associated with cardiovascular death and MACE in diabetic 
patients. The risk of cardiovascular outcomes (total mortality, cardiovascular mortality and 
MACE events) was higher, with an independent association between DM and increased 
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Atrial fibrillation (AF) is the commonest arrhythmia in clinical practice and represents a major 
healthcare burden, with an increased risk of stroke and thromboembolism, as well as other 
cardiovascular events, hospital admissions and mortality. The prevalence of AF is greater in 
patients with associated comorbidities, such as hypertension, heart failure, chronic kidney 
disease or diabetes mellitus (DM) (1,2,3).  
DM is one of the most common chronic conditions, whereby the incidence in Western countries 
is increasing and approximately 9% of European adults acquire this disease (4). The 
association between DM and increased cardiovascular risk is well known (5). AF and DM 
frequently coexist and about one out of five diabetic patients suffer also from AF(6). The 
mechanisms of this association are not completely understood, but include atrial electrical, 
structural, electromechanical and autonomic remodelling, playing an important role in the 
development of AF in individuals affected by this condition (7). Oxidative stress an inflammation 
exacerbate atrial electrical and structural remodelling, predisposing to AF initiation and 
maintenance (8). The effect of glycaemic control on the incidence of new-onset AF is 
controversial, while some authors have found that poor glycaemic control confers higher risk of 
arrhythmia occurrence (9), others have shown that intensive glycaemic control does not seem 
to affect the incidence of new-onset AF (10). On the other hand, some therapies used in 
diabetic patients, eg. metformin (11), thiazolidinediones (12), angiotensin-converting enzyme 
inhibitors (ACEI) and angiotensin II receptor blockers (ARB) (13) could be associated with a 
decreased risk of developing AF. Moreover, given the possible link between oxidative stress 
and inflammation and AF occurrence, therapeutic strategies targeting these pathways might be 
useful for combatting diabetes-related AF (8).  
When AF and DM present together the coexistence of other associated comorbidities is higher 
and the risk of cardiovascular events seems even greater. In the EORP-AF (EURObservational 
Research Programme-Atrial Fibrillation) General Registry, the prevalence of DM was around 
20%; these patients were older and had a higher prevalence of comorbidities, worse quality of 
life, and greater all-cause, cardiovascular and non-cardiovascular mortality (14). Furthermore, 











episodes seem to have worse clinical outcomes in the presence of this metabolic disorder (15, 
16). Thus, most of these individuals will require long-term oral anticoagulation. Although VKA 
efficacy does not seem to be reduced in DM-related AF, higher international normalized ratio 
(INR) variability has been observed in these patients (17). On the other hand, current evidence 
suggests at least comparable efficacy and safety of DOAC in DM-related AF (18). 
 
The aim of our study was to investigate the prevalence of DM and other comorbidities in a ‘real-
world’ multicentric prospective cohort of anticoagulated AF patients included in the FANTASIIA 
registry. Second, we evaluated the incidence of adverse events during follow-up as well as the 
differences in clinical management and quality of anticoagulation depending on the presence or 













The FANTASIIA (Spanish acronym for ‘Fibrilación Auricular: Influencia del Nivel y Tipo de 
Anticoagulación Sobre la Incidencia de Ictus y Accidentes hemorrágicos’) registry is an 
observational, prospective, national and multicentre study of clinical and demographic 
characteristics of Spanish AF patients. The study design of FANTASIIA registry has been 
described previously (19). In brief, the main objective was to assess the incidence of 
thromboembolic and bleeding events in an unselected population of patients with AF, 
specifically the type of oral anticoagulant (VKA or DOAC) used and the quality of 
anticoagulation control with VKAs.  
Study Population  
Between June 2013 and March 2014, all outpatients with confirmed diagnosis of paroxysmal, 
persistent or permanent AF, were prospectively enrolled. All patients included in the registry had 
been receiving OAC (VKA or DOAC) for at least 6 months before enrolment. By design, each 
investigator included 16 patients taking VKA therapy and 4 patients who were taking DOAC 
treatment. The study was conducted in 50 outpatient clinics by 80 investigators (81% 
cardiologists, 11% general practitioners and 8% internists). Patients with valvular heart disease 
(rheumatic valve disease, moderate-severe valve disease and prosthesis or valve repair 
surgery), younger than 18 years or with recent hospital admission were excluded.  
All patients provided signed informed consent. The study was conducted according to the 
ethical principles of Declaration of Helsinki and Good Clinical Practice Guidelines and was 
approved by the Clinical Research Ethics Committee at Hospital Universitario de San Juan 
(Spain) with the approval number 12/220 and by the Spanish Agency of Medicine and Health 
Products as a prospective follow-up post-authorization study with the approval number SEC-
ACO-2012–01. 
Data Collection  
Clinical and demographic data for all AF patients were collected. Patients were classified as 
being diabetic if they were under treatment with insulin or other antidiabetic therapiesor, for 
patients without antidiabetic therapy, those who met the 2004 American Diabetes Association 
criteria (fasting plasma glucose  126 mg/dL in 2 occasions and/or 2-hour plasma glucose value 
during a 75 g oral glucose tolerance test  200mg/dL). For assessing glycaemic control in 
people with diabetes, basal glycated haemoglobin (HbA1c) and subsequent values during 
follow-up were registered. Poor glycaemic control was defined as one or more measurements of 
HbA1c over 7.5%. Previous heart disease was defined as the composite of coronary artery 
disease (CAD), heart failure and other structural cardiomyopathies (such as hypertrophic 











using the CHADS2 (15) (congestive heart failure, hypertension, age ≥ 75 years, diabetes 
mellitus, stroke or transient ischaemic attack) and CHA2DS2-VASc scores (16) (congestive heart 
failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischaemic attack, 
vascular disease, age 65–74 years and sex category [female]). Bleeding risk was calculated 
using the HAS-BLED score (20) (hypertension [uncontrolled systolic blood pressure >160 mm 
Hg], abnormal renal and/or liver function, previous stroke, bleeding history or predisposition 
(anaemia), labile INR [only applies to a VKA user; not applicable for a non-VKA user], elderly 
[age ≥65 years], and concomitant drugs [antiplatelet or non-steroidal anti-inflammatory drugs] 
and/or alcohol excess). Indeed, we assessed the fragility of the population according to 
Charlson comorbidity index. The latter is the most widely used comorbidity index to predict 1-
year mortality in patients based on comorbidity data (21). In order to evaluate AF related 
symptoms and patients’ perception of their health status, the European Heart Rhythm 
Association (EHRA) functional class score was used (1). 
Quality of anticoagulation control  
For patients treated with VKA, coagulation status was determined by monthly INR values 6 
months before the study inclusion, 6 months after baseline, and at 1 year of follow-up. All 
available INR of each patient in the 6 months previous were collected at baseline with at least 1 
INR per month to calculate the time in the therapeutic range (TTR). The FANTASIIA registry is 
an observational multicentre registry. For that reason, the frequency of the INR determinations 
to maintain the INR between 2.0 and 3.0 and the frequency of visits to the physicians were 
performed following the usual clinical practice without any additional intervention. The TTR was 
estimated according to different methods. The main methodology employed was the classical 
linear interpolation method of Rosendaal (22); however, the quality of anticoagulation also was 
studied according to the direct method or percentage of INR in therapeutic range (PINRR). This 
method calculates the TTR according to the number of visits where the INR is in therapeutic 
range (between 2.0 and 3.0) and divides it by the total number of visits. Poor quality of 
anticoagulation or "INR lability" was defined when patients experienced a TTR <65% or < 70%. 
Clinical Outcomes  
Follow-up started the day of the inclusion for 12 months. Thromboembolic events were defined 
as stroke or transient ischaemic attack (TIA) and peripheral artery embolism. All strokes were 
evaluated by computed tomographic (CT) scan or magnetic resonance imaging (MRI), 
according to the neurologist criteria. Major bleeding events were assessed according to the 
2005 International Society of Thrombosis criteria (23): bleeding in a critical anatomical site 
(intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial or intramuscular 
with compartment syndrome) and/or bleeding causing a fall in Hb ≥20 g/L, or transfusion of ≥2 
units of packed red blood cells. We also recorded all-cause mortality and cardiovascular 











syndrome, heart failure, lethal arrhythmia or sudden death, artery aneurysm rupture or stroke). 
Major adverse cardiovascular event (MACE) was defined as the composite of ischaemic stroke, 
myocardial infarction and cardiovascular mortality. To guarantee the quality of the FANTASIIA 
registry, an external event assignment committee was formed to evaluate all adverse events.  
Statistical Analyses  
Normal distribution of continuous variables was tested with the Kolmogorov-Smirnov method. 
Continuous variables are presented using the mean ± standard deviation or median 
(interquartile range). Categorical variables are expressed as percentages. For comparisons 
among groups, T-student test was used in the case of continuous variables and the Chi- square 
test for qualitative variables. Cox regression analyses were used to determine the associations 
between DM and mortality, bleeding and cardiovascular events. The independent effect of 
clinical variables on adverse clinical outcomes was calculated using a Cox proportional hazards 
regression, including in the multivariate model only those values with p < 0.15 on univariate 
analysis. Differences in event-free survival were examined with log-rank test and Kaplan–Meier 
curves were drafted accordingly. Statistical significance was defined as p < 0.05. Statistical 
















Baseline characteristics, comorbidities and symptoms. 
 
We enrolled 2,178 patients in FANTASIIA registry (1,648 patients treated with VKAs and 530 
patients treated with DOAC). A total of 1,956 patients (89.8% of the total sample) completed 1 
year of follow-up and were included in the analysis. Mean age of the patients was 73.8 ± 9.5 
years and 56.0% were male. 574 (29.3%) of the patients had DM, most of them, 559 (28.6%), 
had type 2 DM, whereas only 15 (0.7%) suffered from DM type 1. 
 
Clinical and demographic baseline characteristics classified according to the presence of DM 
are summarized in Table 1. No differences were found in the age and sex of diabetic versus 
non-diabetic individuals. Diabetic patients had significantly higher prevalence of associated risk 
factors and comorbidities, such as hypertension, dyslipidaemia, lung disease, kidney disease, 
peripheral artery disease and heart disease (heart failure and ischaemic heart disease). Thus, 
their Charlson comorbidity index was significantly higher (2.0±1.1 vs0.8±0.9;p<0.001). 
Haemoglobin (Hb) levels and glomerular filtration rates (GFR) were significantly lower in 
patients with DM. As expected, thromboembolic and major bleeding risks were significantly 
higher in these patients (CHA2DS2-VASc score: 4.7±1.5 vs 3.3±1.5; p<0.001, HAS-BLED score: 
2.3±1.1 vs 1.9±1.0; p<0.001). HbA1c levels were available for 536 diabetic patients, of which 
143 (26.7%) had bad glycaemic control (HbA1c>7.5%). 
 
When evaluating AF related symptoms, we found that DM was associated with worse functional 
class, with most diabetic patients classed as EHRA functional class II or III, while non-diabetics 
were mostly class I (p<0.001).  
 
Regarding AF subtypes and management, diabetic patients had a higher percentage of long-
standing persistent or permanent AF, in contrast with non-diabetics, who had more paroxysmal 
or persistent AF (p=0.04). A rhythm control strategy was less used in diabetic patients vs non-
diabetic (40.1% vs 33.6%; p=0.007).  Diabetics more commonly received diuretics, angiotensin-
converting enzyme inhibitors (ACEI), aldosterone-receptor inhibitors (ARI), statins and digoxin. 
Non-diabetic patients were treated more frequently with calcium antagonists.  
 
Anticoagulation treatment and control. 
 
In FANTASIIA, 1484 patients (75.8%) were taking VKA and 472 (24.2%) DOAC, with no 
differences between diabetic and non-diabetics (p=0.21). Of those taking VKA, those with DM 
had poorer anticoagulation control (mean TTR by Rosendaal method:58.5±24.4% vs 
62.7±25.3%; p=0.002). When we compared the percentage of patients who were outside 











diabetics with TTR<65%; p=0.001 and 65.5% vs 56.3% had TTR<70%; p=0.001). 
 
Clinical outcomes. 
After a median follow-up of 1077 days (IQR: 766-1113 days), DM patients had a higher risk of 
major bleeding  [HR 1.41 (IC95% 0.99-2.01); p=0.056], myocardial infarction [HR 2.04 (95%CI 
1.17-3.53); p=0.01], cardiovascular mortality [HR 2.40 (95%CI 1.62-3.56);p<0.001], total 
mortality [HR 1.58 (95%CI 1.20-2.07);p<0.001] and MACE [HR 2.03 (95%CI 1.47-2.80); 
p<0.001] (Table 2). We found no differences in stroke between both groups [HR 0.98 (95%CI 
0.51-1.88); p=0.95]. 
An association between glycated haemoblobin levels and risk of major bleeding was found (HR 
1.79; 95%CI 1.01-3.18; p=0.047; however, HbA1c levels did not show a significant relationship 
with other outcomes: total mortality (HR 1.38; 95%CI 0.88-2.16; p=0.16), cardiovascular 
mortality (HR 1.53; 95%CI 0.83-2.82; p=0.17) and stroke (HR: 1.41; 95%CI 0.45-4.40; p=0.55). 
Glycaemic control was not related with quality of anticoagulation control (p=0.35). 
Figure 1 shows the incidence of the different outcomes in diabetic patients depending on quality 
of anticoagulation control. The incidence of cardiovascular death [(14.12 vs 4.89%;p=0.001 for 
TTR<65 vs ≥65%);(13.36 vs 4.55%;p=0.003 for TTR<70 vs ≥70%)] and MACE [(16.79 vs 
9.78%;p=0.03 for TTR<65 vs ≥65%);(16.44 vs 9.09%;p=0.03 for TTR<70 vs ≥70%)] was 
significantly greater in diabetic patients with lower TTR. 
Cox logistic regression analysis showed an independent association between DM and 
cardiovascular mortality [HR 1.73 (95%CI 1.07-2.80); p=0.024]. Table 34 summarises clinical 
factors related to the different adverse events on multivariate Cox regression analysis. 
Differences in event-free survival for mortality, major bleeding and MACE depending on the 













In the FANTASIIA Registry, which included nearly 2,000 patients with AF, almost 30% of the 
patients had concomitant DM, which was associated with additional comorbidities and higher 
thromboembolic and bleeding risks. Second, quality of anticoagulation control with vitamin-K 
antagonists was poorer in this group. Third, the risk of adverse cardiovascular outcomes and 
death was higher in diabetic individuals and an independent association with cardiovascular 
death was evident.  
 
The proportion of patients with DM in this Spanish registry (almost one-third) is similar to that of 
the ORBIT-AF Registry, which included nearly 10,000 AF individuals from the United States 
(24),and slightly higher than the number of diabetics from the EORP-AF Registry (14), with 
3100 European individuals. These great burden of DM among patients with AF reflects not only 
the contemporary increasing prevalence of both conditions (4,25), but also an incremented risk 
for the development of AF in diabetic patients (6). Other studies have shown that DM is an 
independent risk factor for the occurrence of AF, with higher risk associated with longer duration 
and worse glycaemic control (9). Although the mechanisms of this relationship are not 
completely understood, metabolic defects in DM cause endothelial dysfunction, abnormal 
activation of the renin-angiotensin-aldosterone system and acceleration of atherogenesis. 
Indeed, DM could cause structural, electrical, electromechanical and autonomic atrial 
remodelling, leading to an increased susceptibility to AF occurrence (7)(26). 
 
Our study showed that diabetic AF patients, when compared to non-diabetics, had significantly 
more associated risk factors and comorbidities, such as hypertension, dyslipidaemia, pulmonary 
disease, renal disease, heart failure, ischaemic heart disease and peripheral artery disease. 
Moreover, the presence of DM was associated to a worse functional class. Although a possible 
role of neuropathy masking cardiac subjective symptoms in DM has been suggested (27), our 
findings are consistent with previous European and north-American registries, which also 
showed that diabetics are more symptomatic and have worse health-related quality of life and 
greater functional impairment than non-diabetics (14)(24). We used the EHRA score, an 
instrument to assess AF-related symptoms, not only palpitations, but also fatigue, dizziness, 
dyspnea, chest pain and anxiety, which may be more related to the severity of heart disease 
and other underlying conditions. Interestingly, in the ORBIT-AF registry, patients with diabetes 
less often reported palpitations or syncope, but they reported significantly more dyspnea upon 
exertion or at rest, exercise intolerance and fatigue (24). In contrast with the EORP-AF, where 
diabetic individuals were older than non-diabetics, and the ORBIT-AF, where diabetics were 
younger, the age of the Spanish AF patients with DM was similar from that of those without DM, 
and therefore age could not explain our findings. As a result of the higher prevalence of 
coexisting risk factors, and similar to previous reports, both thromboembolic and major bleeding 











in individuals with DM (14)(24).  
 
In the FANTASIIA registry, pharmacological treatment and AF management differed between 
the group of patients with DM and non-diabetics: diuretics, ACEI, ARI and statins were more 
frequently prescribed if DM was present, given the higher prevalence of hypertension and other 
comorbidities in this group.  
 
Importantly, we confirm that diabetic patients are significantly less likely to undergo a rhythm 
control strategy. One possible explanation is the lower prevalence of paroxysmal or persistent 
AF. Also, the higher prevalence of concomitant risk factors and other diseases (as expressed by 
higher Charlson index) could make physicians less prone to indicate cardioversion or ablation, 
given that the presence of one or more risk factors increases the risk of arrhythmia recurrence 
after ablation by 30% (28). These is also a lower success rate of both cardioversion and 
subsequent maintenance of sinus rhythm in patients with DM (29), with a possible relationship 
to glycaemic control (30). 
 
All the patients that entered our registry were taking anticoagulant treatment, most (about 75%) 
being VKAs. No difference was found between the use of VKAs or DOAC depending on the 
presence of DM. We found that globally 55% of AF patients had poor anticoagulation control 
(31). To our knowledge, quality of anticoagulation in diabetic patients with AF has been poorly 
studied. In the EORP-AF registry, information about anticoagulation control was not available 
(14). In this substudy of the FANTASIIA we demonstrated that more than two-thirds of diabetic 
patients had a TTR lower than recommended, and TTR was significantly worse in DM than in 
non-DM individuals. Nelson and co-workers previously demonstrated that comorbidities were 
associated with lower TTR, specifically heart failure and DM (32). In the Chinese Atrial 
Fibrillation registry, DM and other comorbidities, such as coronary heart disease and peripheral 
artery disease were associated with increased variability in INR (33). Indeed, one of our most 
outstanding findings is that we specifically demonstrate that among diabetic individuals, poorer 
TTR confers an increased risk of cardiovascular death and MACE. Therefore, more attention 
should be paid on trying to achieve better quality of anticoagulation control when VKAs are used 
in individuals with DM, given that this population is particularly susceptible to cardiovascular 
outcomes. 
 
One of the main findings of our study is that, compared with non-diabetics, AF patients with DM 
had worse prognosis at follow-up, with more than two-fold risk for cardiovascular mortality, even 
after covariate adjustment. The risk for major bleeding, myocardial infarction, total mortality and 
MACE was also doubled compared to non-diabetics. Nevertheless, we could not demonstrate a 
difference in the occurrence of stroke between both groups. In the ORBIT-AF Study outcomes 
also differed between AF patients without and with DM, having the latter an increased risk of 











to bleeding (24). In the EORP-AF Registry, DM was also an independent predictor of all-cause 
mortality and coronary events, but the incidence of stroke or TIA and major bleeding was no 
different between groups(14). Interestingly, the European Prevention of thromboembolic 
events–European Registry in Atrial Fibrillation (PREFER in AF) demonstrated that the sole 
presence of DM not requiring insulin did not increase thromboembolic risk, as only insulin-
dependent diabetics had significantly higher risk of thromboembolism, compared to non-insulin 
type 2 DM and non-diabetics (34).  However, previous data from earlier trials had identified DM 
as an independent risk factor for thromboembolism (35). One possible explanation for the lack 
of influence of DM on thromboembolic risk is the greater use of anticoagulant treatment in all 
these newer registries (100% in FANTASIIA), leading to a lower incidence of stroke and 
embolism in both groups.     
 
Strengths and limitations 
 
The FANTASIIA is a multicentre nation-wide registry, with large sample size, a prospective 
design and a long follow-up. Clinical characteristics and coagulation status of the patients 
included were thoroughly collected. Moreover, to guarantee the quality of the data, an external 
event assignment committee evaluated all adverse outcomes. A detailed statistical analysis, 
with strong adjustment for confounders, allowed us to compare clinical characteristics and long-
term outcomes between the groups with and without DM. A substantial number of events took 
place in each category to estimate the association between this metabolic syndrome and 
adverse outcomes. Our findings are robust and consistent with previous literature. 
 
There are several limitations that need to be considered. First, as an observational registry, it 
has the inherent limitations of all observational studies. Second, most of our patients were on 
anticoagulant treatment with VKA, and the one most used in our country is acenocoumarol, 
which has a shorter half-life than warfarin, but similar TTR. For these reasons, and even if our 
sample is representative of the Spanish population, our results might not be fully extrapolated to 
other countries using other VKA. Furthermore, less than a quarter of the individuals received 
DOAC, thus, we cannot assure if our outcomes apply to populations with higher use of these 
anticoagulants. Another limitation of our study is that almost all the diabetic patients included 
had type 2 DM, with only very few having DM type 1, for that reason our conclusions should 
only apply to type 2 diabetics. Fifth, the presence of more comorbidities at baseline in diabetic 
individuals could have influenced our findings, and even if multivariate analysis showed that the 
impact on cardiovascular outcomes was independent of the coexistence of other risk factors, 
residual confounding may remain despite multivariate analysis. Regarding DM management, we 
did not have information about antidiabetic therapies and the possible influence of these 
medications on our outcomes could not be analysed. Finally, data on glycaemic control were 
not available for the whole sample, we believe that this may be a reason for the lack of 















In the FANTASIIA Registry, a significant proportion of the patients with AF had DM. Patients 
with DM had more associated comorbidities, poorer quality of anticoagulant treatment and 
underwent significantly less rhythm-control strategies for AF. The risk of developing adverse 
cardiovascular outcomes and death was higher in diabetic patients, particularly in those with 
worse quality of anticoagulation control. An independent association between DM and 
cardiovascular mortality was found in AF patients.  
 
TABLE 1. Comparison of baseline clinical characteristics according to the presence of 
diabetes. 





Age (years) 73.7±9.7 73.9±.,9 0.96 
Sex (female) 608 (44.7) 242 (42.3) 0.35 
Comorbidities 
Hypertension (%) 1053 (76.2) 520 (90.6) <0.001 
Dyslipidaemia (%) 666 (48.3) 354 (61.7) <0.001 
COPD/SAS (%) 219 (15.9) 123 (21.4) 0.004 
Renal disease (%) 229 (16.6) 148 (25.8) <0.001 
PAD (%) 68 (4.9) 50 (8.7) 0.001 
Previous stroke (%) 229 (16.6) 102 (17.8) 0.545 
Previous bleeding (%) 44 (3.2) 36 (6.3) 0.002 
Heart disease (%) 593 (43.0) 344 (59.9) <0.001 
Heart failure (%) 341 (24.7) 213 (39.0) <0.001 
CAD (%) 200 (14.5) 156 (27.0) <0.001 
Hb (g/dL) 13.8±1.7 13.2±1.7 <0.001 
GFR (mL/min) 67.2±22.8 63.7±23.2 <0.001 
BMI (kg/m2) 28.5±4.5 30.0±5.5 <0.001 
Charlson Index (Media) 0.8±0.9 2.0±1.1 <0.001 
CHADS2 score (Media) 1.9±1.0 3.2±1.1 <0.001 
CHA2DS2-VASc score (Media) 3.3±1.5 4.7±1.5 <0.001 
HAS-BLED score (Media) 1.9±1.0 2.3±1.1 <0.001 
Concomitant treatment 
Diuretics 52.5 69.2 <0.001 
ACEI 29.2 34.7 0.02 
ARI 37.6 48.1 <0.001 
Statins 50.1 66.9 <0.001 
Beta-blockers 59.4 62.5 0.20 
Digoxin 16.9 21.1 0.03 
Calcium-antagonists 77.3 72.6 <0.001 
Antiarrhythmicdrugs 25.6 22.3 0.12 
Rhythm control strategy 40.1 33.6 0.007 
Anticoagulant therapy 











DOAC 24.9 22.3  
TTR1 (mean±SD) 62.7±25.3 58.5±24.4 0.002 
TTR1< 65% 49.8 58.8 0.001 
TTR1< 70% 56.3 65.5 0.001 
TTR2 (mean±SD) 66.1±24.5 61.5±23.1 <0.001 
COPD: chronic obstructive pulmonary disease; SAS: sleep apnea syndrome; PAD: peripheral 
artery disease; CAD: coronary artery disease; Hb: haemoglobin; GFR: glomerular filtration rate; 
ACEI: angiotensine-converting enzyme inhibitors; ARI: aldosterone-receptor inhibitors; VKA: 
vitamin K antagonists; DOAC: direct oral anticoagulants; SD: standard deviation.1TTR 
calculated by Rosendaal method. 2TTR calculated by direct method.  
 
 
TABLE 2. Cardiovascular outcomes according to the presence of diabetes. 











48 (2.45) 35 (2.53) 13 (2.26) 0.73 






32 (2.32)         
5 (15.63)         
5 (15.63)         
22 (68.75) 
13 (2.26)         
2 (15.38)         
1 (7.69)         
10 (76.92) 
0.94 
Major bleeding 146 (7.46) 93 (6.73) 53 (9.23) 0.05 
Myocardial 
infarction 
53 (2.70) 29 (2.10) 24 (4.18) 0.001 
Total mortality 255 (13.03) 158 (11.43) 97 (16.9) 0.001 
Cardiovascular 
mortality 
107 (5.47) 55 (3.98) 52 (9.06) <0.001 
MACE 168 (8.58) 94 (6.8) 74 (12.89) <0.001 
 
TIA: transient ischemic attack; MACE: Major adverse cardiovascular event (composite of 













TABLE 3. Clinical factors related to adverse outcomes by multivariate Cox regression 
analysis. 
 
 HR 95% CI p-value 
 Major bleeding 
Renal disease 1.56 1.06-2.28 0.023 
HAS-BLED score 1.29 1.08-1.55 0.005 
 Total mortality 
Age 1.09 1.07-1.11 <0.001 
Heart failure 1.71 1.25-2.34 0.001 
Charlson index 1.33 1.15-1.54 <0.001 
HAS-BLED score 1.34 1.16-1.55 <0.001 
 Cardiovascular mortality 
DM 1.73 1.07-2.80 0.024 
Age 1.08 1.05-1.12 <0.001 
Heart failure 2.42 1.49-3.91 <0.001 
Charlsson index 1.27 1.02-1.58 0.03 
HAS-BLED score 1.27 1.02-1.57 0.03 
 MACE 
Age 1.05 1.03-1.08 <0.001 
Ischaemic heart 
disease 
1.91 1.34-2.73 <0.001 
Heart failure 1.90 1.23-2.93 0.004 













FIGURE 1. Cardiovascular outcomes in diabetic patients according to Time in 
Therapeutic Range. 
 









TTR: time in therapeutic range; MACE: Major adverse cardiovascular event (composite 

























































































































































































































FIGURE 2. Kaplan Meier survival curves for the different outcomes according to the 
presence of diabetes.  
A) Total mortality (p<0.001) 
 
 

























Table 4. What is known and what the study adds to current knowledge on diabetes 
related atrial fibrillation.  
WHAT IS KNOWN 
Atrial fibrillation and diabetes frequently coexist.  
The risk of cardiovascular events seems greater in diabetes-related atrial fibrillation. 
WHAT THE STUDY ADDS 
A significant proportion (30%) of atrial fibrillation patients have diabetes. 
Atrial fibrillation patients with diabetes are more likely to have other comorbidities.  
Among those under vitamin K antagonists, coagulation status was more unstable than in non-
diabetic individuals.  
Diabetic subjects were less prone to undergo a rhythm control strategy.  
The risk of developing adverse cardiovascular outcomes and death was greater in diabetic 
patients, particularly with lower TTR, and an independent association with cardiovascular 
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